Recent activity highlights a mixed view on Regeneron Pharmaceuticals (REGN). Several institutional investors including Mufg Securities Americas Inc., Nissay Asset Management Corp Japan ADV, Humankind Investments LLC, and Graham Capital Management L.P. have recently acquired shares. Citigroup upgraded its rating for REGN to 'Buy' and raised its price target. A teenage scientist won Regeneron's $100K Global Innovation Prize by reducing antiviral drug costs. Regular stock trades were reported by various entities. However, Q1 2025 revenues fell short of expectations, largely due to lower demand for Eylea, a key product. Despite this, Dupixent sales surged 19%. REGN also presented a $7B growth plan and announced a capacity expansion through a $3B partnership with Fujifilm. A lawsuit has been lodged over Eylea's pricing practices, with some questioning REGN's transparency. Despite the FDA not extending dosing for EYLEA HD, the current regimen remains approved. The upcoming Q1 earnings report is awaited with interest. Overall, the situation combines new investment, innovation recognition, potential product volatility, and legal challenges.
Regeneron Pharmaceuticals REGN News Analytics from Sun, 02 Mar 2025 08:00:00 GMT to Sat, 17 May 2025 11:39:24 GMT - Rating 0 - Innovation 7 - Information 10 - Rumor -2
